Please ensure Javascript is enabled for purposes of website accessibility

Here's Why ShockWave Medical Stock Is Perking Up This Week

By George Budwell – Jan 13, 2022 at 11:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Buyout rumors have been swirling around this mid-cap medtech company this week.

What happened

Shares of the medtech company ShockWave Medical (SWAV -2.27%) rose by as much as 11.2% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence. Investors have been bidding this mid-cap medtech equity up this week following multiple reports that the company is considering a possible takeover bid.

Over the weekend, Bloomberg News reported that fellow mid-cap medical device company Penumbra (PEN 1.31%) was exploring a merger with ShockWave. In response, ShockWave was said to be working with an advisor to study the feasibility of a tie-up with another healthcare company

Wooden blocks that spell M&A sitting on the keyboard of a laptop computer.

Image source: Getty Images.

So what

Since this initial report, however, Wells Fargo analyst Larry Biegelsen noted that the more likely scenario is a full-on buyout offer from one of the industry's larger entities such as Abbott Laboratories, Abiomed, Boston Scientific, or Medtronic. Penumbra, after all, may not have the financial firepower to entice an in-demand company into a friendly merger. Keeping with this theme, Penumbra's market cap is less than $3 billion greater than ShockWave's at the moment. Medtech giants such as Abbott, Boston Scientific, and Medtronic, on the other hand, would have no such problem. Each of these companies could easily offer top dollar for ShockWave in a buyout scenario.  

Now what

Is ShockWave likely to get bought out? Medtech has historically been a hotbed of M&A activity. So it wouldn't be surprising if ShockWave is indeed the next takeover target in medtech. The company, after all, sports a high-value medical device system used to treat calcified cardiovascular disease -- a commercial opportunity of approximately $8.5 billion a year, according to ShockWave's own estimates.

The issue -- if there is one -- will likely be the price. ShockWave's shares are currently trading at over 13 times 2022 projected revenue. That's not an outrageous valuation for a medtech company, especially for one expected to experience a long period of revenue growth. But it isn't exactly cheap, either. A buyer would thus have to be willing to absorb this built-in premium, and then be willing to add another $2 billion to $3 billion to the pot to make a takeover worthwhile for ShockWave and its stakeholders. 

George Budwell has no position in any of the stocks mentioned. Wells Fargo is an advertising partner of The Ascent, a Motley Fool company. The Motley Fool owns and recommends Abiomed and ShockWave Medical. The Motley Fool recommends Penumbra. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.